Ardana plc (LSE:ARA) today announces positive results of its testosterone cream in a Phase II study in Hypogonadal Men. This Phase II dose-finding study provided clear evidence of the effectiveness of Ardana’s bi-gel technology for the transdermal delivery of testosterone.
